SNGX Quote, Financials, Valuation and Earnings

Citius Oncology, Inc. has a net margin of -1636.63% compared to Soligenix, Inc.'s net margin of --. Soligenix, Inc.'s return on equity of -248.07% beat Citius Oncology, Inc.'s return on equity of -64.23%.

Soligenix, Inc. has a consensus price target of $17.50, signalling upside risk potential of 1322.76%. On the other hand Citius Oncology, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 455.56%. Given that Soligenix, Inc. has higher upside potential than Citius Oncology, Inc., analysts believe Soligenix, Inc. is more attractive than Citius Oncology, Inc..

Soligenix, Inc. has a beta of 2.005, which suggesting that the stock is 100.536% more volatile than S&P 500. In comparison Citius Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Soligenix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soligenix, Inc. pays -- of its earnings as a dividend. Citius Oncology, Inc. pays out -- of its earnings as a dividend.

Soligenix, Inc. quarterly revenues are --, which are smaller than Citius Oncology, Inc. quarterly revenues of --. Soligenix, Inc.'s net income of -$2.5M is higher than Citius Oncology, Inc.'s net income of -$5M. Notably, Soligenix, Inc.'s price-to-earnings ratio is -- while Citius Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soligenix, Inc. is -- versus -- for Citius Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -1636.63% compared to Soligenix, Inc.'s net margin of 10.24%. Soligenix, Inc.'s return on equity of -248.07% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Soligenix, Inc. has a consensus price target of $17.50, signalling upside risk potential of 1322.76%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that Soligenix, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Soligenix, Inc. is more attractive than Amicus Therapeutics, Inc..

Soligenix, Inc. has a beta of 2.005, which suggesting that the stock is 100.536% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

Soligenix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soligenix, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Soligenix, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Soligenix, Inc.'s net income of -$2.5M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Soligenix, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soligenix, Inc. is -- versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -1636.63% compared to Soligenix, Inc.'s net margin of -259.95%. Soligenix, Inc.'s return on equity of -248.07% beat Insmed, Inc.'s return on equity of -193.23%.

Soligenix, Inc. has a consensus price target of $17.50, signalling upside risk potential of 1322.76%. On the other hand Insmed, Inc. has an analysts' consensus of $215.10 which suggests that it could grow by 39.69%. Given that Soligenix, Inc. has higher upside potential than Insmed, Inc., analysts believe Soligenix, Inc. is more attractive than Insmed, Inc..

Soligenix, Inc. has a beta of 2.005, which suggesting that the stock is 100.536% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.

Soligenix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soligenix, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Soligenix, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Soligenix, Inc.'s net income of -$2.5M is higher than Insmed, Inc.'s net income of -$370M. Notably, Soligenix, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soligenix, Inc. is -- versus 65.53x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding Corp. has a net margin of -1636.63% compared to Soligenix, Inc.'s net margin of -972.95%. Soligenix, Inc.'s return on equity of -248.07% beat Tonix Pharmaceuticals Holding Corp.'s return on equity of -62.54%.

Soligenix, Inc. has a consensus price target of $17.50, signalling upside risk potential of 1322.76%. On the other hand Tonix Pharmaceuticals Holding Corp. has an analysts' consensus of $66.33 which suggests that it could grow by 285.44%. Given that Soligenix, Inc. has higher upside potential than Tonix Pharmaceuticals Holding Corp., analysts believe Soligenix, Inc. is more attractive than Tonix Pharmaceuticals Holding Corp..

Soligenix, Inc. has a beta of 2.005, which suggesting that the stock is 100.536% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding Corp. has a beta of 1.897, suggesting its more volatile than the S&P 500 by 89.736%.

Soligenix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soligenix, Inc. pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding Corp. pays out -- of its earnings as a dividend.

Soligenix, Inc. quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding Corp. quarterly revenues of $3.3M. Soligenix, Inc.'s net income of -$2.5M is higher than Tonix Pharmaceuticals Holding Corp.'s net income of -$32M. Notably, Soligenix, Inc.'s price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soligenix, Inc. is -- versus 9.27x for Tonix Pharmaceuticals Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.